meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic glioblastoma (mGB) - 2nd line (L2)
head and neck cancer squamous cell cancer (HNSCC)
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs cisplatin
vs Standard of Care (SoC)
vs HER inhibitor
vs EGFR inhibitor
vs cetuximab based chemotherapy
vs cetuximab alone
vs cetuximab plus platin plus 5FU
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs tremelimumab
vs anti-PD-(L)1
vs durvalumab based treatment
vs durvalumab alone
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab based treatment
pembrolizumab plus 5FU plus platin
Comparator:
vs cetuximab plus platin plus 5FU;
Risk of bias:
low;
some concerns;
high;
NA;